5 Reasons Why HIMS Is Poised for a Major Breakout
Hims & Hers Health (HIMS) has been one of our best-performing holdings since I first added it to the 10X Stocks portfolio two-and-a-half years ago. But 2025 has dealt a vicious “one-two” punch to our favorite telehealth company, combining a declining stock market with the recent revocation of HIMS’ ability to offer GLP-1 weight loss drugs. The result has been a significant drawdown in HIMS’ share price, even though the stock is still up over 126% in the last year.
Read More